Brian Hilberdink is an accomplished executive with over 20 years of global and domestic experience developing and executing the strategy for Novo Nordisk A/S, one of the world’s largest biotechnology companies. In his current role as President of Novo Nordisk Canada, he has significantly increased investment in Canada, launched several innovative products in the therapy areas of diabetes, obesity and hemophilia, and the company has been recognized as one of the countries country’s top 100 employers. Brian is an active contributor on the Board of Innovative Medicines Canada and Biotech Canada, and is also a founding member of the Diabetes Canada Impact Council and the City of Mississauga’s Life Science Consortium. Previous to his current role, Brian was a Corporate Vice President in Global Marketing for Novo Nordisk A/S in Copenhagen, Denmark, leading the launch of the company’s future insulin portfolio; at the time, this represented the single largest investment that was ever been made in the history of diabetes drug development. He also has experience working in the United States, where he led several of the commercial teams during a period of significant growth and investment
I was speaking to a friend recently about a perception many have of pharmaceutical companies, and the impact of this industry on society.
The story of insulin is one of collaboration—its discovery, development and continued innovation made possible by a common goal of changing diabetes.
As the leader of a Canadian company focused on improving the health of Canadians, supporting individuals in their pursuit of healthy living continues to be a big source of motivation.